reports
Kongsberg Gruppen ASA: 1 director
A director at Kongsberg Gruppen ASA maiden bought 5,000 shares at 358.610NOK and the significance rating of the trade was 66/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last tw...
Scorpio Tankers Inc. Announces Financial Results for the Fourth Quarte...
Scorpio Tankers Inc. Announces Financial Results for the Fourth Quarter of 2025 and an Increase to Its Quarterly Dividend MONACO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Scorpio Tankers Inc. (NYSE: STNG) ("Scorpio Tankers" or the "Company") today reported its results for the three months ended December 31, 2025. The Company also announced that its board of directors (the "Board of Directors") has declared a quarterly cash dividend on its common shares of $0.45 per share. Results for the three months ended December 31, 2025 and 2024 For the three months ended December 31, 2025, the Company had...
- ABGSC Capital Goods Research
- Martin Mauseth
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Grant of Restricted Stock Units and Warrants to Employees in Genmab Company Announcement COPENHAGEN, Denmark; January 29, 2026 – (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 32,806 restricted stock units and 34,307 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, ...
Scorpio Tankers Inc. Announces that on February 12, 2026, the Company ...
Scorpio Tankers Inc. Announces that on February 12, 2026, the Company Plans to Issue Its Fourth Quarter 2025 Results and Have a Conference Call MONACO, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Scorpio Tankers Inc. (NYSE: ) ("Scorpio Tankers," or the "Company") announced today that on Thursday, February 12, 2026, the Company plans to issue its fourth quarter 2025 earnings press release in the morning (Eastern Standard Time) and host a conference call at 9:00 AM Eastern Standard Time and 3:00 PM Central European Time. Conference Call Information Title: Scorpio Tankers Inc. Fourth Quarter 2025 Co...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2025
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2025 Company Announcement Net sales of DARZALEX® in 2025 totaled USD 14,351 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; January 21, 2026 – (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by J&J were USD 14,351 million in 2025. Net trade sale...
Scorpio Tankers Inc: 1 director
A director at Scorpio Tankers Inc sold 20,000 shares at 57.771USD and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) f...
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Company Announcement Based on the topline results from the EPCORE® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss next steps COPENHAGEN, Denmark; January 16, 2026 – (Nasdaq: GMAB) today announced topline results from the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, which demonstrated an improvement in progress...
- ABGSC Capital Goods Research
- Martin Mauseth
Scorpio Tankers Inc. Announces Update on its Liquidity, Outstanding De...
Scorpio Tankers Inc. Announces Update on its Liquidity, Outstanding Debt, and Vessel Purchase Commitments MONACO, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Scorpio Tankers Inc. (NYSE:STNG) (“Scorpio Tankers,” or the “Company”) announced today an update on its liquidity, outstanding debt, and its forward newbuilding vessel commitments. Update on Current Liquidity and Debt The table below summarizes the Company’s outstanding indebtedness and liquidity as of the dates presented, and on a pro-forma basis to illustrate the impact of announced vessel sales and debt repayments that are pending closing...
Scorpio Tankers Inc. Announces a Vessel Sale Agreement
Scorpio Tankers Inc. Announces a Vessel Sale Agreement MONACO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Scorpio Tankers Inc. (NYSE:STNG) (“Scorpio Tankers,” or the “Company”) announced today that it has entered into an agreement to sell the 2015 built scrubber-fitted LR2 product tanker, STI Kingsway. The selling price is $57.5 million, and the sale is expected to close within the first or second quarter of 2026. About Scorpio Tankers Inc. Scorpio Tankers Inc. is a provider of marine transportation of petroleum products worldwide. Scorpio Tankers Inc. currently owns or lease finances 93 product...
Genmab Partners with Anthropic to Accelerate Research and Development ...
Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence Media ReleaseCOPENHAGEN, Denmark; January 07, 2026 Supports Genmab’s ambition to build an AI-enabled innovation model that advances the company’s vision of bringing transformative antibody medicines to patients (Nasdaq: GMAB) announced today a partnership with Anthropic to advance and enhance the company’s research and development (R&D) processes through the adoption of cutting-edge artificial intelligence (AI) capabilities. Under the agreement, Genmab and Anthropic will de...
Genmab to Present at the 44th Annual J.P. Morgan Healthcare Conference
Genmab to Present at the 44th Annual J.P. Morgan Healthcare Conference Media ReleaseCOPENHAGEN, Denmark; January 5, 2026 (Nasdaq: GMAB) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco at 3:45 PM PST / 6:45 PM EST on January 13, 2026, 12:45 AM CET on January 14, 2026. The live and archived webcast of the presentation will be available on Genmab’s website at . About Genmab Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other ...
Scorpio Tankers Inc. Announces Time Charter-Out Agreements
Scorpio Tankers Inc. Announces Time Charter-Out Agreements MONACO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Scorpio Tankers Inc. (NYSE:STNG) (“Scorpio Tankers,” or the “Company”) announced today that it has entered into agreements to time charter-out the 2015 built LR2 product tankers, STI Rose and STI Alexis. The term of each agreement is five years at a rate of $29,000 per vessel per day. These time charters are expected to commence in the first quarter of 2026. About Scorpio Tankers Inc. Scorpio Tankers Inc. is a provider of marine transportation of petroleum products worldwide. Scorpio Tan...
Genmab Portfolio Prioritization Update
Genmab Portfolio Prioritization Update Company Announcement Genmab to discontinue clinical development of acasunlimab following a portfolio reviewDecision reflects prioritization of higher‑impact opportunities across Genmab’s late‑stage pipeline and increasingly competitive landscapeThis decision does not impact Genmab’s full‑year 2025 financial guidance COPENHAGEN, Denmark; December 29, 2025 – (Nasdaq: GMAB) announced today that it will discontinue further clinical development of acasunlimab. This decision was made as part of Genmab’s strategic focus on the most value‑creating opportuni...
Scorpio Tankers Inc. Announces Agreements to sell Two LR2 Product Tank...
Scorpio Tankers Inc. Announces Agreements to sell Two LR2 Product Tankers and to Purchase Two LR2 Newbuilding Product Tankers MONACO, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Scorpio Tankers Inc. (NYSE:STNG) (“Scorpio Tankers,” or the “Company”) announced today that it has entered into agreements to sell two, 2016 built LR2 product tankers and to purchase two scrubber-fitted LR2 newbuilding product tankers. Vessel Sales The Company has entered into agreements to sell the 2016 built LR2 product tankers, STI Goal and STI Gallantry for $52.3 million per vessel. These sales are expected to close w...
Genmab Announces Completion of Tender Offer for Outstanding Common Sha...
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period Company Announcement Transaction adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolioTransaction anticipated to be accretive to Genmab’s EBITDA by end of 2029 COPENHAGEN, Denmark; December 12, 2025 – (Nasdaq: GMAB) (“Genmab”) announced today that the conditions, including the minimum tender condition, to the previously announced tender offer (the “Offer”) by Genmab Holding II B.V., a wholly owned subsidia...
Genmab to Hold 2025 R&D Update and ASH Data Review Meeting
Genmab to Hold 2025 R&D Update and ASH Data Review Meeting Media Release Event to be held virtually via live webcast and archived on Copenhagen, Denmark; December 11, 2025 – (Nasdaq: GMAB) will hold its 2025 R&D Update and ASH Data Review Meeting today, December 11, 2025 at 11:00 AM Eastern Time (5:00 PM CET / 4:00 PM GMT). The event will take place virtually and can be attended via live webcast. To register for the webcast, click . An archive of the webcast will be available on Genmab’s website. This meeting is not an official program of the ASH Annual Meeting. About Genmab Genmab i...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.